Microsatellite Instability and Mutation of DNA Mismatch Repair Genes in Gliomas

Suet Yi Leung, Tsun Leung Chan, Lap Ping Chung, Annie S. Y. Chan, Yiu Wah Fan, Kwan Ngai Hung, Wai Kay Kwong, Judy W. C. Ho and Siu Tsan Yuen

From the Departments of Pathology, Surgery and Radiation Oncology, and the Hereditary Gastrointestinal Cancer Registry, Queen Mary Hospital, The University of Hong Kong, Hong Kong

Microsatellite instability (MSI) has been identified in various human cancers, particularly those associated with the hereditary nonpolyposis colorectal cancer syndrome. Although gliomas have been reported in a few hereditary nonpolyposis colorectal cancer syndrome kindred, data on the incidence of MSI in gliomas are conflicting, and the nature of the mismatch repair (MMR) defect is not known. We established the incidence of MSI and the underlying MMR gene mutation in 22 patients ages 45 years or less with sporadic high-grade gliomas (17 glioblastomas, 3 anaplastic astrocytomas, and 2 mixed gliomas, grade III). Using five microsatellite loci, four patients (18%) had high level MSI, with at least 40% unstable loci. Germline MMR gene mutation was detected in all four patients, with inactivation of the second allele of the corresponding MMR gene or loss of protein expression in the tumor tissue. Frameshift mutation in the mononucleotide tract of insulin-like growth factor type II receptor was found in one high-level MSI glioma, but none was found in the transforming growth factor β type II receptor and the Bax genes. There was no family history of cancer in three of the patients, and although one patient did have a family history of colorectal carcinoma, the case did not satisfy the Amsterdam criteria for hereditary nonpolyposis colorectal cancer syndrome. Three patients developed metastatic colorectal adenocarcinomas, fitting the criteria of Turcot’s syndrome. Thus, MSI and germline MMR gene mutation is present in a subset of young glioma patients, and these patients and their family members are at risk of developing other hereditary nonpolyposis colorectal cancer syndrome-related tumors, in particular colorectal carcinomas. These results have important implications in the genetic testing and management of young patients with glioma and their families. (Am J Pathol 1998, 153:1181–1188)
genes has been found in a high proportion of these young patients with MSI, but little is known of the MSI status or mutation of the MMR genes in the young patients with gliomas. Using stringent criteria for MSI, we examined a series of local young patients with high-grade gliomas (grades III to IV by the World Health Organization system), to look for the presence of MSI and examined for mutation, both somatic and germline, in the hMSH2 and hMLH1 genes.

Materials and Methods

Materials

Twenty-two patients, ages 45 years or less, with gliomas of grades III to IV, were included in this study. The mean age of the patients was 33 years (range, 13 to 44). The tumors included 17 glioblastomas, 3 anaplastic astrocytomas, 2 mixed gliomas (grade III), and the histological classification used was based on the World Health Organization system. Either frozen or paraffin-embedded tumor tissue with more than 80% tumor cell content was used. For normal tissue, either blood leukocytes obtained by venipuncture with the patients' consent or normal brain tissue adjacent to the tumor was used. For all tissue used for DNA extraction, frozen or paraffin sections were used to confirm the absence of tumor cell contamination in the normal tissues and to confirm the percentage of tumor in tumor blocks. DNA and RNA were extracted from blood leukocytes and frozen tumor blocks for germline and somatic MMR gene mutational analysis using standard methods.

MSI Analysis

Paired tumor and normal tissues were amplified by polymerase chain reaction (PCR) using 5 microsatellite loci. These included dinucleotide repeats (Tp53, D18S58, and D2S123) and polyadenine tracts (Bat40 and Bat26/A26). Tp53 was purchased from Research Genetics (Huntsville, AL). D18S58, D2S123, and Bat40 were synthesized according to the sequence published previously. For the polyadenine tract in intron 5 of the hMSH2 gene, two pairs of primers were used, including Bat40 as previously published, and another pair named A26, corresponding to nucleotides 123 to 143 (forward) and nucleotides 222 to 241 (reverse) of the hMSH2 exon 5 genomic sequence (GenBank accession no. U41210). In all cases, all five loci were analyzed.

The PCR was performed in a 10-μl reaction solution containing 50 ng of DNA, 10 mmol/L of Tris (pH 8.3), 50 mmol/L of KCl, 2 to 3 mmol/L of MgCl₂, 200 μmol/L of deoxynucleotide triphosphates, 1 μCi [α-32P]dCTP, 0.2 to 1 μmol/L of each primer, and 0.1 U Taq polymerase. A hot-start reaction was performed by preheating the mixture in the thermocycler at 95°C for 5 minutes, then cooling to 80°C before adding the Taq polymerase. An initial denaturation step of 95°C for 5 minutes and 25 to 40 cycles, including 95°C for 45 seconds (1 minute), 1 minute (1.5 minutes) in 52 to 64°C annealing temperature according to the specific primers, and 72°C for 1 minute (2 minutes) in frozen DNA (paraffin DNA), was performed, followed by a final extension of 5 minutes at 72°C.

The PCR products were diluted by loading buffer, heated at 95°C for 5 minutes, and loaded onto 6% vertical polyacrylamide gel. After electrophoresis, the gels were fixed, dried, and exposed to X-ray film for 12 hours to 7 days.

The results were interpreted independently by two observers. Results with discrepancy in interpretation were discussed and PCR was repeated if necessary. MSI was defined as the presence of allelic shift or additional bands in the tumor compared with normal tissue. All cases with MSI were repeated once. A case was defined as high-level MSI if there were more than 40% unstable loci, low-level MSI if less than 40%, and microsatellite stable if there were no unstable loci.

MSI in the (A)10 tract of type II transforming growth factor β receptor (TβRII), (G)8 tracts of Bax, and insulin-like growth factor type II receptor (IGFIIIR) genes was also analyzed in the microsatellite-unstable cases. The primer sequences were as described previously.

hMSH2 and hMLH1 Mutational Analysis

Mutational analysis for hMSH2 and hMLH1 was performed for the high-level MSI cases using the following methods.

In Vitro Synthesized Protein Assay

In vitro-synthesized protein assays to screen for truncation mutations in the MMR genes hMSH2 and hMLH1 were performed with primer sequences as described. In brief, 3 μg of total RNA was reverse transcribed using 20 to 200 ng of random hexamers or oligo(dT), 20 units of RNasin, 20 pmol of deoxynucleotide triphosphates, and 200 units of Superscript II reverse transcriptase (Life Technologies, Inc., Grand Island, NY) in a 20-μl reaction volume, using the manufacturers' suggested reaction conditions. Forty cycles of PCR were performed in 50 μl and included 2 to 4 μl of first-strand cDNA mix, 10 mmol/L of Tris-HCl (pH 8.3), 50 mmol/L of KCl, 3 to 5 mmol/L of MgCl₂, 5 pmol of each primer, 200 μmol/L of each nucleotide, and 2.5 units Taq polymerase (Life Technologies). Both hMSH2 and hMLH1 were amplified in two overlapping segments ranging between 1.2 and 2.0 kb. The left-hand primers of each segment were tagged with a T7 promoter sequence and a translation initiation site. The products were then subjected to in vitro transcription/translation using the linked T7 transcription-translation system (Amersham Corp., Little Chalfont, UK).

DNA Sequencing Analysis

Individual exons of hMSH2 and hMLH1 genes, including intron-exon boundaries, were PCR amplified. The primers' sequences are available on request. The PCR products were then purified by High Pure PCR Product Puriﬁcation Kit (Boehringer Mannheim, Mannheim, Germany)
and directly sequenced by Sequenase V2.0 (Amersham) using both forward and reverse primers following the manufacturer’s protocols. The sequencing products were denatured at 80°C for 5 minutes and electrophoresed through a 6% polyacrylamide/urea gel at 70 W for 2 to 3 hours. The gels were then fixed, dried, and exposed to autoradiographic films.

**Immunohistochemistry**

Immunostaining for hMSH2 and hMLH1 was performed in the cases showing allelic shift in one or more loci, using the standard streptavidin-biotin-peroxidase complex method with 3,3'-diaminobenzidine as chromogen. Sections 6 μm thick of 10% neutral buffered formalin-fixed, paraffin-embedded tumor tissue were incubated for 1 hour at 37°C with monoclonal antibodies against the amino-terminal fragment (clone GB12; dilution 1:20; Oncogene Research Products, Cambridge, MA) and carboxy-terminal fragment of hMSH2 (clone FE11; dilution 1:200; Oncogene Research Products, Cambridge, MA). For hMLH1, sections were incubated at 37°C for 1 hour using a monoclonal antibody (clone G168-15; dilution 1:10; PharMingen, San Diego, CA). Microwave pretreatment at 95°C for 30 minutes in citrate buffer, pH 6.0, was performed after deparaffinization. For negative control, the primary antibodies were replaced by mouse immunoglobulin G (Dakopatts, Glostrup, Denmark).

**Results**

**MSI**

Four of the 22 high-grade gliomas from patients ages 45 years or less (18%) showed high-level MSI (Table 1). These included three glioblastomas and one malignant mixed glioma. In all four cases, there was gross MSI with 75 to 100% loci involved. One additional tumor showed MSI in one locus only, and this case was thus considered low-level MSI. None of the tumors showed mutation in the mononucleotide tracts in the TpRII and Bax genes. One tumor showed frameshift mutation in the (G)₈ tract of the IGFIR gene. Representative results of the microsatellite analysis are shown in Figure 1 and 2.

**Clinicopathological Data and Family History**

The clinical data of the four patients with high-level MSI gliomas are shown in Table 2. The patients were all relatively young; two of them were below 30 when they developed the glioblastoma. Histologically, the three glioblastomas showed primitive anaplastic cells in the background and the presence of many multinucleated

---

**Table 1. Results of Microsatellite Analysis and Immunohistochemistry for Cases Showing MSI**

<table>
<thead>
<tr>
<th>Patients</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex/age</td>
<td>F/27</td>
<td>M/23</td>
<td>M/35</td>
<td>M/37</td>
<td>F/38</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>GBM</td>
<td>Mixed glioma (grade III)*</td>
<td>GBM</td>
<td>GBM</td>
<td>Astro III</td>
</tr>
<tr>
<td>Tp53</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>D18S58</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>D2S123</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bat40</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Bat26/A26†</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>% loci with MSI</td>
<td>75%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>20%</td>
</tr>
<tr>
<td>TpRII (A)₉₀</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bax (G)₈₀</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IGFIR (G)₈₀</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>hMSH2 protein (IHC)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>hMLH1 protein (IHC)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

GBM, glioblastoma multiforme; Astro III, anaplastic astrocytoma; IHC, immunohistochemistry.
†Both Bat26 and A26 amplify a polyadenine tract in intron 5 of the hMSH2 gene.
*According to World Health Organization system.

---

**Figure 1. MSI at various loci in gliomas.** A, Tp53; B, D2S123; C, D18S58; D, Bat26, E, A26; and F, Bat40. N, normal; T, tumor.
tumor giant cells. Patient B had a malignant mixed glioma, with a prominent oligodendroglial element, although ependymal and astrocytic elements were noted in some areas. None except patient D had a family history of cancer. Patient D had a positive family history of colorectal carcinoma, but that did not satisfy the Amsterdam criteria for HNPCC syndrome. Interestingly, three of the patients had metachronous colorectal adenocarcinomas, thus satisfying the criteria of Turcot's syndrome. Patient A was only 27 years old when she developed a glioblastoma, and there was no previous tumor nor any family history of cancer.

**Germline and Somatic Mutation of the MMR Genes**

All four patients with high-level MSI gliomas showed germline mutation of the MMR genes, three of them in the hMSH2 and one in hMLH1 (Table 2). Three of the mutations resulted in truncated protein products. One case (patient D) showed a missense mutation resulting in amino acid substitution in an evolutionary conserved residue. The wild-type allele was lost in the tumor in this patient.

In three cases, a second hit could be identified in the gliomas. Patient A showed two truncated protein products in the in vitro-synthesized protein assay of the tumor RNA (Figure 3). The germline mutation was found in exon 8 of the hMLH1 gene, which resulted in skipping of the exon (Figure 4A and 5). A second mutation, found only in the tumor DNA, resulted in a stop codon (Figure 4B). For patients C and D, the normal allele was absent when tumor tissue was sequenced (Figure 6). For patient B, the wild-type allele was retained in sequencing of exon 11 in the brain tumor. We did not screen for other somatic mutation in the hMSH2, because only paraffin blocks of the tumor were available.

**Expression of the hMSH2 and hMLH1 Protein**

Immunohistochemical staining revealed complete loss of hMSH2 protein when both antibodies on the tumor cells in patients B, C, and D were used, whereas the normal neurons and glial cells at the tumor borders were posi-

---

**Table 2. Clinical Data and DNA MMR Gene Mutations in Four Patients with Microsatellite-Unstable Gliomas**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex/age</th>
<th>Histology</th>
<th>Family history</th>
<th>Other cancers (age, years)</th>
<th>Survival after craniotomy</th>
<th>MMR germline mutation</th>
<th>MMR somatic mutation in glioma</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>F/27</td>
<td>GBM</td>
<td>None</td>
<td>None</td>
<td>Died of disease at 8 months</td>
<td>hMLH1 last nucleotide of exon 8 (CGG→CAG), resulting in splicing defect, skipping of exon 8, deletion of codon 197–226, and frameshift</td>
<td>hMLH1 exon 13, codon 487 CGA→TGA(stop)</td>
</tr>
<tr>
<td>B</td>
<td>M/23</td>
<td>Malignant mixed glioma</td>
<td>Colon (25)</td>
<td>Died of disease (brain) at 4 years</td>
<td>hMSH2 exon 11 codon 580 GAA→TAA(stop)</td>
<td>Not determined; (absence of hMSH2 protein by immunostaining)</td>
<td>Wild-type allele loss in tumor by sequencing</td>
</tr>
<tr>
<td>C</td>
<td>M/35</td>
<td>GBM</td>
<td>Not available (adopted son)</td>
<td>Colon (29)</td>
<td>Alive with disease (brain) at 6 months</td>
<td>hMSH2 first nucleotide of exon 12 codon 587, deletion of G (agGCT→agGT), generating a stop codon 6 bp downstream</td>
<td>Wild-type allele loss in tumor by sequencing</td>
</tr>
<tr>
<td>D</td>
<td>M/37</td>
<td>GBM</td>
<td>Two sisters had colorectal adenocarcinomas</td>
<td>Rectum (28)</td>
<td>Died of disease (brain) at 0.5 months</td>
<td>hMSH2 exon 3 codon 199 (TG→GC) resulting in change of an evolutionary conserved cysteine to arginine</td>
<td>Wild-type allele loss in tumor by sequencing</td>
</tr>
</tbody>
</table>

GBM, glioblastoma multiforme.
Staining for hMLH1 was retained in the tumors in these three patients. The tumor cells in patient A were negative for hMLH1 but positive for hMSH2 proteins, whereas the normal cells were positive for both.

**Discussion**

Three important pieces of information resulted from this study. 1) A proportion of young patients (18%) with high-grade gliomas showed gross replication error, characteristic of defects in the DNA MMR system. 2) In all of these patients with gross replication errors, germline mutation in one of the MMR genes could be detected. 3) In three of the four cases, inactivation of the second allele was found in the tumor tissue. Although the second hit could not be detected in patient B, the tumor cells were immuno-histochemically negative for hMSH2, supporting the presence of a second inactivating event. This double-hit phenomenon for MMR genes, identical to Knudson’s theory for a tumor suppressor gene, was also previously suggested in HNPCC-related and sporadic colorectal carcinomas.

To our knowledge, this is the first study documenting the presence of a germline MMR gene mutation in young patients with sporadic gliomas. A similar study in young patients with sporadic colorectal carcinoma revealed MSI in 58%, with germline MMR mutation detected in 42% of the MSI-positive cases. Although germline MMR gene mutation has previously been found in four patients with Turcot's syndrome, patient A developed and died.

---

**Figure 3.** In vitro synthesized protein assay of 5' (A) and 3' (B) segments of the hMLH1 gene from the glioblastoma of patient A. The bands with highest molecular weight and strongest intensity correspond to the normal products. Truncated products of 21 and 18 kDa (arrowheads) are noted in the 5’ and 3’ segments. Lanes C, blood leukocytes from a normal individual as control; lanes T, glioblastoma.

**Figure 4.** A: Sequencing result of hMLH1 exon 8 from the blood leukocytes (lanes N) and glioblastoma (lanes T) of patient A. Both tumor and blood leukocytes demonstrate a mutation in the last nucleotide of exon 8, CG to CA (arrow), indicating that it is a germline mutation. B: Sequencing result of hMLH1 exon 13 from the blood leukocytes (lanes N) and glioblastoma (lanes T) of patient A. Somatic mutation in codon 487, CGA to TGA (arrow), generating a stop codon, is found in the tumor but not in blood leukocytes.

**Figure 5.** Reverse transcription-PCR analysis using a pair of primers amplifying nucleotides 471 to 813 of hMLH1 cDNA. A wild-type band of 342 bp and an abnormal band of 253 bp (arrow), resulting from skipping of exon 8, are noted in the RNA extracted from the leukocytes of patient A (lane A) compared with a normal individual (lane C). Lane M: Bluescript-MSP1 marker.
of the glioma without antecedent cancer. Patient B presented with the glioma first and only subsequently developed the colorectal carcinoma. Neither A nor B had a family history of cancer. Two other patients have antecedent colorectal carcinoma. In patient D, a family history of colorectal carcinomas was also obtained. This raises an important point concerning the management of young patients with microsatellite-unstable gliomas and their family members. From the information in our study, we conclude that screening for replication error is useful in young patients with high-grade gliomas. For high-level MSI patients, germline mutation of the MMR gene should be sought. Regular colonoscopic screening for colorectal carcinoma should be offered to the patient and the family members with demonstrable MMR gene mutation. Also, we should be alert to and check for the possibility of brain tumor by regular neurological examination. It is of note that, whereas the colorectal carcinoma could be successfully treated, three of the patients succumbed to the gliomas 0.5 months to 4 years after the craniotomy. This was in contrast to the prolonged survival noted in three patients with MSI-positive glioblastoma in a previous series.23

Concerning the histological type of high-level MSI gliomas, three were glioblastomas. Interestingly, one case was a malignant mixed glioma with a prominent oligodendroglial component and also focal ependymal differentiation. In HNPCC kindred, the possible histological type of brain tumor includes not only astrocytomas but also oligodendrogliomas and rarely ependymomas.21 Thus, mutation of the MMR gene may lead not only to glioblastomas, but to high-grade gliomas of oligodendroglial or even ependymal differentiation.

Mononucleotide tracts of various growth-regulatory genes are frequently the target of mutational inactivation in microsatellite-unstable tumors. The (A)\textsubscript{10} tract in the TP\textsubscript{BII} gene is mutated in 70 to 90% of microsatellite-unstable colorectal and gastric cancers.36,41 Frameshift mutation of the (G)\textsubscript{p} tract in Bax is also reported in more than 50% of these cancers.37,42,43 Apart from frameshift mutation in the (G)\textsubscript{p} tract, somatic mutation of Bax genes is frequent in MSI-positive gastric and colorectal carcinomas,43 but not in gliomas.44 Interestingly, none of the MSI-positive gliomas in this study showed mutation in the TP\textsubscript{BII} and Bax genes. This may be the result of selection pressure, in which mutation of genes caused by MMR defects are selected for if they confer growth advantage in that organ.

We identified a frameshift mutation in the IGFIIR gene in the malignant mixed glioma from patient B, the first reported mutation in this gene in a glioma, although IGFIIR mutation has been reported in MSI colorectal, gastric, and endometrial carcinomas.48 IGFIIR plays a role in activation of transforming growth factor \(\beta\), which is a potent growth inhibitor. Also, it antagonizes the growth-stimulatory effect of IGFII by internalizing and degrading the protein.47 Given that enhanced expression of IGFIIR mRNA has been reported in gliomas,48 inactivating mutation of IGFIIR may remove the growth-inhibitory signal and confer growth advantage.

The molecular genetic pathways of different subsets of glioblastoma have been increasingly clarified in recent years.29,49 Those arising de novo are referred to as primary glioblastomas, and those developed from a pre-existing astrocytoma are referred to as secondary glioblastomas. Most primary glioblastomas develop in older patients (mean, 55 years) with epidermal growth factor receptor amplification or overexpression, loss of heterozygosity in chromosome 10, and p16 deletion. Secondary glioblastomas tend to occur in younger patients (mean, 39 years), and most of them harbor p53 mutations.50–54 We have demonstrated that a proportion of primary glioblastomas in young patients can be caused by germline MMR gene mutations, and these patients and their family members are at risk of developing other HNPPC-related tumors, in particular colorectal carcinomas. Screening for MSI and MMR gene mutation is thus of importance in the management of these patients.

Acknowledgments

We thank Mr. Samson W. C. Shum for the technical assistance, Miss Kedo Kwan for collecting the family history, and Dr. R. J. Collins for his assistance with the manuscript.

References


46. Dennis PA, Rifkin DB: Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor. Proc Natl Acad Sci USA 1991, 88:580–584


